Applications
Potential commercial applications for Mobious’ platform technology are as broad and far-reaching as genetic analysis itself.
The technologies will be directly applicable to the research and diagnostic markets. Our approaches – all of which circumvent dominant and restrictive intellectual property - should mean that it will be possible to deliver significant commercial and scientific benefits via enhanced functionality, such as higher levels of multiplexing, reduced costs and shorter process times.
In particular, we believe that our Molecular Resonance Sequencing™, Ampliplex™ and Accelaffin™ platforms have the potential to transform existing genetic analysis markets and applications, and create entirely new market opportunities. In the near term, Mobious’ strategic focus is to develop applications in fields such as ultra-highly multiplexed real-time PCR, array based sequencing-by-synthesis, single molecule sequencing, and accelerated biochip hybridisation.
Potential commercial applications for Mobious’ platform technology are as broad and far-reaching as genetic analysis itself.
The technologies will be directly applicable to the research and diagnostic markets. Our approaches – all of which circumvent dominant and restrictive intellectual property - should mean that it will be possible to deliver significant commercial and scientific benefits via enhanced functionality, such as higher levels of multiplexing, reduced costs and shorter process times.
In particular, we believe that our Molecular Resonance Sequencing™, Ampliplex™ and Accelaffin™ platforms have the potential to transform existing genetic analysis markets and applications, and create entirely new market opportunities. In the near term, Mobious’ strategic focus is to develop applications in fields such as ultra-highly multiplexed real-time PCR, array based sequencing-by-synthesis, single molecule sequencing, and accelerated biochip hybridisation.